Agenus (AGEN) Stock Forecast & Price Target

Agenus is viewed positively because botensilimab plus balstilimab is showing repeatable, differentiated efficacy across tumor types, including 72% pCR in high-risk dMMR colon cancer in NEOASIS and 32% pCR with 41% MPR in MSS disease in NEST, with strong ctDNA clearance and low severe toxicity. The durability story is equally important: in recurrent ovarian cancer, 25% of treated patients were alive and off therapy at last follow-up and estimated three-year OS held at 48%, suggesting the regimen can generate long-tail benefit beyond conventional response metrics. That clinical breadth supports the company’s neoadjuvant thesis in MSS colon cancer and underpins a probability-adjusted valuation in which BOT+BAL represents the overwhelming share of modeled value.

Agenus is highly exposed to binary clinical risk because NEST and UNICORN are only early signals, while the ~850-patient ROBBIN Phase 3 study must prove that pathologic responses and ctDNA clearance translate into a statistically significant, clinically meaningful EFS benefit. As a pre-commercial biotech, it also faces substantial funding pressure: the recent $85M financing is expected to last through 3Q27, but the additional ~$255M from milestone-linked warrants is not guaranteed, and any delay or shortfall could force dilutive financing on unfavorable terms. Competitive and execution risks further cloud the outlook, since BOT+BAL has not yet been validated in a randomized registrational setting and rivals in MSS CRC may erode its development lead before approval is secured.